Peter Cox
About Peter Cox
Peter Cox is the Vice President of Drug Discovery at BenevolentAI in London, with over 20 years of experience in the pharmaceutical and biotechnology industries.
Current Role at BenevolentAI
Peter Cox is the Vice President of Drug Discovery at BenevolentAI, based in London, United Kingdom. Cox has been with BenevolentAI since 2016, initially joining as Associate Exploratory Director. In his current role, Cox oversees various facets of drug discovery efforts, leveraging advanced artificial intelligence technologies to enhance pharmaceutical research and development.
Past Experience at Pfizer Neusentis
Peter Cox worked at Pfizer Neusentis in Cambridge, United Kingdom, from 2001 to 2016. During his 15-year tenure, he held positions including Senior Principal Scientist and Associate Research Fellow. His work centered on neuroscience research, contributing significantly to drug discovery and development. His roles involved both hands-on scientific work and leadership responsibilities.
Academic Background
Peter Cox completed his PhD in Molecular Virology from the University of Glasgow, studying from 1991 to 1995. Prior to this, he earned a BSc in Microbiology from the National University of Ireland, Galway. His robust academic background laid a strong foundation for his subsequent career in the pharmaceutical industry, particularly in drug discovery and neuroscience research.
International Experience
Peter Cox's career includes significant international experience. He was a Post Doctoral researcher at INSERM in Paris, France, from 1995 to 1998. Following this, he held a similar position at Cambridge University for one year before transitioning to industry roles. This international exposure has enriched his expertise and provided diverse perspectives in drug discovery and research.
Extensive Experience in Neuroscience Research
Peter Cox has a substantial background in neuroscience research, having worked at the Parke Davis Neuroscience Research Centre and Pfizer Neusentis. His roles have spanned from Senior Scientist to leadership positions, focusing on the development of innovative therapies for neurological conditions. This extensive experience underscores his expertise in both scientific research and pharmaceutical development.